Could less be more? new trial tests shorter seizure drug course for brain tumor patients
NCT ID NCT06442748
First seen Feb 04, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study compares a short course (6 months) versus a long course (2-3 years) of the seizure medicine levetiracetam in 604 adults with brain tumors who have been seizure-free for 6 months. The goal is to see if stopping the drug earlier can reduce side effects like drowsiness and coordination problems without increasing seizures. Participants must have a primary brain tumor, a history of seizures, and be stable on levetiracetam alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEIZURES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manipal Academy of Higher Education
NOT_YET_RECRUITINGUdupi, Karnataka, 576104, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tata Memorial Centre
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.